Rallybio has started a Phase 1/2 study in healthy male patients, evaluating RLYB211, a hyperimmune globulin derived from plasma. RLYB211 is being tested using healthy men so as not to affect any current or future pregnancies prior to assuring the safety of the investigational treatment..